Mizuho raised the firm’s price target on Quest Diagnostics (DGX) to $210 from $190 and keeps an Outperform rating on the shares as part of a Q3 earnings preview for the healthcare facilities and managed care group. Healthcare utilization growth trends decelerated sequentially in Q3 despite easier year-over-year compares, which could indicate stabilizing cost trends, a positive for managed care companies, the analyst tells investors in a research note. The firm expects solid results from hospitals despite admissions trends falling sequentially. It is also “cautiously optimistic” that contract research organization trends have bottomed.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics price target raised to $195 from $192 at Truist
- Quest Diagnostics price target raised to $190 from $185 at Evercore ISI
- Quest Diagnostics price target raised to $190 from $185 at Barclays
- Guardant Health, Quest Diagnostics announce blood-based screening test pact
- Quest Diagnostics partners with Epic for streamlined laboratory testing